During the past decade, Innovative Clinical Research Institute conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Innovative Clinical Research Institute" are "B-Cell Malignancies" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials), "Head and Neck Cancer" (1 trials), "Non-hodgkin Lymphoma" (1 trials) and "Small Lymphocytic Lymphoma" (1 trials). Many other conditions were trialed in "Innovative Clinical Research Institute" in a lesser frequency.

Most popular intervention types in "Innovative Clinical Research Institute" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "INCAGN02385" (1 trials), "INCAGN02390" (1 trials), "Parsaclisib" (1 trials), "Placebo" (1 trials) and "Retifanlimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Innovative Clinical Research Institute" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Innovative Clinical Research Institute". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Innovative Clinical Research Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Innovative Clinical Research Institute, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".